|
|
The 4th World Congress on
Controversies in Urology (CURy)
Paris, France, January 27-30, 2011 |
|
 |
| Group B |
 |
|
Poster Board 1
PLASMA HOMOCYSTEINE IN ESRD PATIENTS
M. Babaei1, S. Gerayeshnejad1, N. Dashti1, K. Abdi1, F. Nazari2
1Tehran University of Medical Sciences, Tehran-Iran; 2Zanjan University of Medical Sciences,Tehran-Iran
Poster Board 3
BONE-MARKER LEVELS AND POTENTIAL CORRELATION WITH OUTCOMES IN PATIENTS WITH RENAL CANCER AND BONE METASTASIS: PRELIMINARY RESULTS OF TUGAMO TRIAL
E. Esteban1, J.L. lvarez-Ossorio2, M.A. Climent3, H. Ascaso4,
A. Gonzalez del Alba5, B. Mellado6, F. Vazquez7, V. Calderero8, I. Chirivella9,
J.M. Fernandez1, B. Gonzalez
1Hospital Central de Asturias, Oviedo; 2Hospital Puerta del Mar, Cadiz; 3Instituto Valenciano de Oncologia, Valencia; 4Hospital Universitari Joan XXII, Tarragona; 5Hospital Son Dureta, Mallorca; 6Hospital Clinic i Provincial de Barcelona; 7Hospital Universitario Virgen de las Nieves, Granada; 8Hospital Universitario Miguel Servet, Zaragoza; 9Hospital Clinico de Valencia, Valencia, Spain
Poster Board 4
HIGH INCIDENCE OF RENAL CELL CARCINOMA IN PATIENTS WITH HISTORY OF DIABETES
S.L Habib1,2, T.J Prihoda3, M. Luna2, S.A. Werner3
1Geriatric Research, Education, and, Clinical Center, South Texas Veterans Healthcare System, San Antonio, Texas
2Department of Medicine & 3Department of Pathology, University of Texas Health Science Center and San Antonio, Texas, USA
Poster Board 5
RADIOFREQUENCY ABLATION IN TREATMENT OF RENAL TUMOURS
M. Jasinski1, J. Siekiera1, K. Kamecki1, A. Krasnicki1, W. Mikolajczak1, A. Petrus1,
A. Wronczewski1, W. Jozwicki2, T. Drewa1,3
1Department of Oncological Urology, Oncology Centre Bydgoszcz, Poland
2Department of Pathology, Oncology Centre Bydgoszcz, Poland
3Department of Tissue Engineering, Nicolaus Copernicus University, Bydgoszcz, Poland
Poster Board 6
LAPAROSCOPIC RADICAL NEPHRECTOMY FOR TUMORS <10 cm
N.G Kalogeras2, S. Giannakopoulos1, T. Pantazis1, S. Giannopoulos1, G. Tsakaldimis1,
E. Patris1, S. Touloupidis1
1Department of Urology, Democritus University of Thrace, Alexandroupolis, Greece & 2General Hospital of Karditsa, Department of Urology, Karditsa, Greece
Poster Board 8
CAN WE CORRELATE TREAT THE KIDNEY CANCER WITH INTRA-OPERATIVE HEMOSTASIS? ESTABLISHING MODEL FOR SPECIFIC HEMOSTASIS BIOMATERIALS COVERED WITH CYTOSTATICS ON A MOUSE C57B1/J KIDNEY MELANOMA
M.S. Nowacki1, A. Jundzill1,2, T.A. Drewa1,3
1Tissue Engineering Department, chair of Medical Biology, Collegium Medicum, Nicolaus Copernicus University in Bydgoszcz, Poland
2Department of General and Vascular Surgery, Collegium Medicum, Nicolaus Copernicus University in Bydgoszcz, Poland
3Division of Clinical Urology & Oncology - Oncology Centre - prof. Franciszek Łukaszczyk memorial hospital in Bydgoszcz, Poland |
Poster Board 13
EFFICACY AND SAFETY OF VARDENAFIL ORODISPERSIBLE TABLET FOR THE TREATMENT OF ERECTILE DYSFUNCTION IN ELDERLY MEN AND THOSE WITH UNDERLYING CONDITIONS
G.A. Dijkman1, H. Sperling2, M. Gittelman3, C. Norenberg4, E. Ulbrich5, S. Ewald4
1Andros Mannenkliniek, Maastricht, The Netherlands
2Kliniken Maria Hilf GmbH, Mönchengladbach, Germany
3Department of Urology, South Florida Medical Research, Aventura, FL, USA
4Bayer HealthCare AG, Wuppertal, Germany
5Bayer Vital GmbH, Leverkusen, Germany
Poster Board 15
SAFETY STUDY OF LONG-ACTING PARENTERAL TESTOSTERONE UNDECANOATE OVER 42 MONTHS
F.A. Saad1,2, A. Haider3, A. Yassin2,4, L. Gooren5
1Bayer Schering Pharma, Scientific Affairs Men's Healthcare, Berlin, Germany
2Gulf Medical University School of Medicine, Ajman, UAE
3Private Urology Praxis, Bremerhaven, Germany
4Institute for Andrology and Urology, Norderstedt, Germany
5Department of Endocrinology, VUmc, Amsterdam, The Netherlands
Poster Board 16
PROSTATE HEALTH & SAFETY PARAMETERS: HYPOGONADAL PATIENTS ON TRT ARE NOT AT HIGHER RISK THAN EUGONADAL SUBJECTS OF AGE-MATCHED CONTROL GROUP -PROSPECTIVE COMPARATIVE 6-YEARS FU ANALYSIS
A. A. Yassin1,2,3, A. D.-J. Yassin4, F.A. Saad5,6
1Institute of Urology & Andrology, Segeberger Kliniken, Norderstedt-Hamburg/Germany
2Dresden International University, Program of Preventive Medicine, Dresden/Germany
3Gulf Medical University School of Medicine, Ajman/UAE
4Asklepios Klinik Barmbek, Dept. of Urology, Hamburg/Germany
5Bayer Schering Pharma AG, Berlin/Germany
6Gulf Medical University School of Medicine, Research Dept., Ajman/UAE |
|
Poster Board 18GENE EXPRESSION OF BCL-2 FAMILY AND PROTEINS INVOLVED IN THE MITOCHONDRIAL TRANSPORT SYSTEMS (V, DAC AND TOMM) AS POSSIBLE MARKER FOR PROSTATE CANCER
A. Asmarinah1, R. Kodariah2, B. Tanurahardja2, C. Arif Mochtar3, Y. Budiningsih4, A. Paradowszka5, K. Steger5,
W. Weidner5, E. Hinsch5
1Department of Medical Biology, Faculty of Medicine, Universitas Indonesia; 2Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia; 3Department of Urology, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital; 4Department of Forensic Medicine and Medicolegal, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
5Department of Urology, Pediatric Urology and Andrology, Justus-Liebig University of Giessen, Germany
Poster Board 19
ACCESS TO INFORMATION AND EXPECTATIONS OF TREATMENT DECISIONS AMONG EUROPEAN PROSTATE CANCER PATIENTS
E.S. Baskin-Bey1, B. Tombal2, C. Schulman3
1Astellas Pharma Europe, Department of Urology, Staines, United Kingdom; 2Cliniques Universitaires Saint-Luc, Avenue Hippocrate, Brussels, Belgium; 3Clinic Edith Cavell and University of Brussels, Brussels, Belgium
Poster Board 20
TREATMENT PATTERNS AND CHARACTERISTICS OF EUROPEAN CASTRATION RESISTANT PROSTATE CANCER (CRPC) PTS
E. Baskin-Bey1, M. Watson1, A. Worsfold2, A. Rider2 B. Tombal3, C. Sternberg4
1Astellas Pharma Europe, Staines, Middlesex, UK; 2Adelphi Real World, Macclesfield, Cheshire, UK; 3Cliniques Universitaires Saint-Luc UCL, Brussels, Belgium; 4San Camillo and Forlanini Hospitals, Rome, Italy
Poster Board 22
THE ROLE OF MENTAL HEALTH STATUS ON QUALITY OF LIFE IN PROSTATE CANCER PATIENTS WHO CHOOSE ACTIVE SURVEILLANCE
L. Bellardita1, D. Villani1, S. Donegani1, R. Salvioni3, S. Stagni3, N. Nicolai3, N. Bedini2, B. Avuzzi2, C. Marenghi1, T. Magnani1, T. Rancati1, R. Valdagni1
1Programma Prostata &2 Radiation Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori & 3Urology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
Poster Board 23
PROSTATE-SPECIFIC ANTIGEN (PSA) PROGRESSION: DEGARELIX VERSUS LEUPROLIDE IN PROSTATE CANCER (PCA)
L. Boccon-Gibod1, B. Tombal2, K. Miller3, F. Schrader4, J.-K. Jensen5, B.-E. Persson6
1Groupe Hospitalier Bichat-Claude Bernard, Paris, France
2Cliniques Universitaires Saint Luc/Universitי Catholique de Louvain, Brussels, Belgium
3Charitי Universitהtsmedizin, Berlin, Germany
4Erasmus University Medical Center, Rotterdam, The Netherlands
5Ferring Pharmaceuticals A/S, Copenhagen, Denmark
6Ferring Pharmaceuticals, Saint-Prex, Switzerland
Poster Board 24
VALUE OF TOTAL TESTOSTERONE AND TOTAL TESTOSTERONE/TOTAL PSA RATIO IN THE DIFFERENTIATION OF PROSTATIC PATHOLOGIES
F.J.S. Botelho1,2, F. Pina1, L. Figueiredo1, F. Cruz1, N. Lunet2
1Department of Urology, S. João Hospital, Porto, Portugal
2Department of Hygiene and Epidemiology, University of Porto Medical School, Porto, Portugal
Poster Board 26
PROSTATE CANCER: A NEWLY DISCOVERED ROUTE FOR TESTOSTERONE TO REACH THE PROSTATE DIRECTLY FROM THE TESTES. NOVEL PATHOPHYSIOLOGICAL MECHANISM
Y. Gat1,2, M. Goren2, S. Joshua2, M. Heiblum1, E. Rosenbaum3
1Weizmann Institute of Science Sub Micron Research; 2Mayanei Hayeshua Hospital, Andrology & Radiology,
3Rabin Medical Center, Department of Oncolgy, Davidoff Research Center, Rehovot, Israel
Poster Board 29
ELEVATED AND/OR RISING PSA IN PRESENCE OF NEGATIVE BIOPSY: CANCER, INFLAMATION OR WATCHFUL WAITING, DILEMMA OF DECISION MAKING
M. Wishahi, A. Nehena, A.M. Elkholy, H.M. Elganzory, H. Nour, E.M. Riad
Urology Department, Theodor Bilharz Research Institute, Cairo, Egypt
Poster Board 30
KOREA PROSTATE BANK
I.G. Kim, J.H. Han, J.Y. Lee, S. Piao, J.Y. Lee
Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul Korea
Poster Board 31
THE CORRELATION BETWEEN HOMOGENEITY OF GLEASON SCORE AT PROSTATE BIOPSY AND PATHOLOGICAL FINDINGS AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH PROSTATE CANCER
W.T. Kim1, S.J. Yun1, S.W. Jo2, Y.W. Kim1, Y.J. Kim1, S.C. Lee1, W.J. Kim
1Department of Urology, Chungbuk National University College of Medicine, Cheongju, Korea
2Department of Urology, Cheongju Saint Mary's Hospital, Cheongju, Korea
Poster Board 33
DIFFERENCES IN THE PROGNOSTIC VALUE OF THE PROSTATE VOLUME, TUMOR VOLUME, AND TUMOR PERCENTAGE BETWEEN PATHOLOGIC T2 AND T3 RADICAL PROSTATECTOMY SPECIMENS
K.H. Lee1, I.C. Cho1, W.A. Kwon1, J.E. Kim1, J.Y. Jeong1,
H.K. Seo1, J.C. Chung1, W.S. Park1, E.K. Hong2
1Center for Prostate Cancer, National Cancer Center; 2Department of Pathology, National Cancer Center, Koyang-si, Korea
Poster Board 41
HUMAN SERUM ADIPONECTIN (ADIPOQ) HAS SIMILAR PRESENCE AMONG DIFFERENT PROSTATE PATHOLOGIES
F.M. Pina1,2, G. Figueiredo3, N. Lunet4,5, F. Botelho2,4,
I. Lopes1,2, T. Lopes1,2, F. Cruz1,2, H. Barros4,5
1Department of Urology, Faculdade de Medicina, Universidade do Porto; 2Department of Urology, 3Department of Immunology, Hospital de São João do Porto; 4Department of Hygiene e Epidemiology, Faculdade de Medicina, U. do Porto & 5Public Health Institute, Universidade do Porto (ISPUP), Portugal
Poster Board 42
ACTIVE SURVEILLANCE FOR PROSTATE CANCER: A NOMOGRAM PREDICTING THE RISK OF UPGRADIG/UPSIZING AT 1 YR RE-BIOPSY
T. Rancati1, R. Valdagni1, M. Colecchia2, R. Salvioni3, S. Villa4, N. Bedini4, D. Biasoni3,
C. Marenghi1, B. Avuzzi1, B. Paolini2,T. Magnani1, S. Catania1
1Scientific Director's Office, Prostate Program, 2Department of Anatomopatholy, 3Department of Urology & 4Department of Radiation Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy
Poster Board 44
STAGING RECTOURINARY FISTULAE AFTER RADICAL PROSTATECTOMY
E. Rijo1, J.A. Lorente1, O. Bielsa1, M. Pera2, A. Francés1, O. Arango1
&
THE POSTERIOR TRANS-SPHINCTERIC-TRANSRECTAL APPROACH (YORK-MASON TECHNIQUE) FOR REPAIR OF RECTO-URINARY FISTULAS AFTER RADICAL PROSTATECTOMY: A SINGLE INSTITUTION EXPERIENCE
E. Rijo1, J.A. Lorente1, O. Bielsa1, M. Pera2, A. Francés1, G. Nohales1, O. Arango1 1Department of Urology, Universitat Autònoma de Barcelona, Hospital del Mar, Barcelona, Spain
2Department of Surgery, Universitat Autònoma de Barcelona, Hospital del Mar, Barcelona, Spain
Poster Board 45
FINAL PATHOLOGY UPGRADE OF PATIENTS WITH LOW RISK PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY
F. Rozet1, F.P. Secin2, R.E. Sanchez-Salas1, V. Flamand1,M. Galiano1, D. Prapotnich1,
A. Mombet1, N. Cathala1, E. Barret1, X. Cathelineau1
1Institut Montsouris, Paris, France
2CEMIC, Buenos Aires, Argentina
Poster Board 46
INTERMITTENT ANDROGEN DEPRIVATION AS SECONDARY THERAPY FOR BIOCHEMICAL RECURRENCE OF LOCALIZED PROSTATE CANCER
R.E. Sanchez-Salas1, D. Prapotnich1, F.P. Secin2, R. Favaretto1, F. Rozet1, M. Galiano1,
E. Barret1, N. Cathala1, A. Mombet1 X. Cathelineau1
1Institut Montsouris, Paris, France
2CEMIC, Buenos Aires, Argentina
Poster Board 47LONG TERM ONCOLOGIC OUTCOMES OF PATIENTS TREATED WITH HIGH INTENSITY FOCUSED ULTRASOUND FOR LOCALIZED PROSTATE CANCER
R.E. Sanchez-Salas1, D. Prapotnich1, F.P. Secin2, R. Favaretto1, E. Barret1, M. Galiano1, F. Rozet1, X. Cathelineau1
1Institut Montsouris, Paris, France
2CEMIC, Buenos Aires, Argentina
Poster Board 48
PIONEERING INSTITUTION MID AND LONG TERM OUTCOMES OF LAPAROSCOPIC RADICAL PROSTATECTOMY
R.E. Sanchez-Salas1, F.P. Secin2, D. Prapotnich1, F. Bianco Jr.3, E. Barret1, F. Rozet1,
M. Galiano1, N. Cathala1, A. Mombet1, X. Cathelineau1
1Institut Montsouris, Paris, France
2CEMIC, Buenos Aires, Argentina
3Columbia University at Miami Florida, USA
Poster Board 49
ROBOTIC PROSTATECTOMY ONCOLOGIC OUTCOMES ACCORDING TO RISK GROUP CLASSIFICATION
R.E. Sanchez-Salas1, F.P. Secin2, D. Prapotnich1, F. Rozet1, M. Galiano1, N. Cathala1,
A. Mombet1, E. Barret1, X. Cathelineau1
1Institut Montsouris, Paris, France
2CEMIC, Buenos Aires, Argentina
Poster Board 50
ROBOTIC PROSTATECTOMY POSITIVE MARGINS LEARNING CURVE
R.E Sanchez-Salas1, F.P. Secin2, D. Prapotnich1, F. Rozet1, M. Galiano1, V. Flamand1,
A. Mombet1, N. Cathala1, E. Barret1, X. Cathelineau1
1Institut Montsouris, Paris, France
2CEMIC, Buenos Aires, Argentina
Poster Board 54
BONE-MARKER LEVELS AND POTENTIAL CORRELATION WITH OUTCOMES IN PATIENTS WITH PROSTATE CANCER AND BONE METASTASIS: PRELIMINARY RESULTS OF TUGAMO TRIAL
F. Vazquez1, A. Gomez Caamaoo2, M.J. Ribal3, L. Leon2, E. Esteban4, C. Gonzalez Enguita5, E. Solsona6, C. Olivier7, J.L. lvarez-Ossorio8, J.A. Contreras8, J. Morote9
1Hospital Universitario Virgen de las Nieves, Granada, Spain; 2Complejo Hospitalario Universitario de Santiago, A Coruסa, Spain; 3Hospital Clinic i Provincial de Barcelona, Spain; 4Hospital Central de Asturias, Oviedo, Spain; 5Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz, Madrid, Spain; 6Instituto Valenciano de Oncologia, Valencia, Spain; 7Hospital Clinico San Carlos, Madrid, Spain; 8Hospital Puerta del Mar, Cadiz, Spain & 9Hospital Universitario de la Vall d’Hebron, Barcelona, Spain
Poster Board 55
MODELING THE PUBLIC HEALTH IMPACT OF RISK REDUCTION OF PROSTATE CANCER (PCA) WITH DUTASTERIDE CHEMOPREVENTION (CP) IN FRANCE
A. Villers1, B. Dervaux2, L. Molinier3, F.-E. Cotte4, P. Grosclaude5, A. Lafuma6, C. Le Fur4, A. Slama4, X. Colin6
1Urology, Universiti Lille Nord de France, Lille, France
2Universiti Droit et Santi Lille 2, Lille, France
3Departement d’Information Medicale, CHU Hotel-Dieu Saint-Jacques, Toulouse, France
4Health Economics & Outcomes Research, GlaxoSmithKline France, Marly le Roi, France
5Tarn Cancer Registry, Albi, France
6Cemka Eval, Bourg la Reine, France
Poster Board 56
SALVAGE AND PRIMARY 17G CRYOABLATION FOR PROSTATE CANCER - A PAN EUROPEAN EXPERIENCE
U.K.F. Witzsch1, D. Greene2, M. Borre3, T. Bjerklund Johansen3
1Klinik fur Urologie und Kinderurologie, Krankenhaus Nordwest, Frankfurt, Germany
2Department of Urology, Sunderland Royal University Hospital, Sunderland, UK
3Urology Department, Aarhus University Hospital, Aarhus, Denmark
Poster Board 59
TESTOSTERONE TREATMENT IN ELDERLY HYPOGONADAL PATIENTS DOES NOT INCREASE PROSTATE CANCER RISK: RESULTS OF A PROSPECTIVE COMPARATIVE STUDY. 6 YEARS FOLLOW UP ANALYSIS TO AGE-MATCHED CONTROLS
A. A. Yassin1,2,3, A. D.-J. Yassin4, A. Haider5, F.A. Saad6,7
1Institute of Urology & Andrology, Segeberger Kliniken, Norderstedt-Hamburg/Germany
2Dresden International University, Program of Preventive Medicine, Dresden/Germany
Gulf Medical University School of Medicine, Ajman/UAE
4Asklepios Klinik Barmbek, Dept. of Urology, Hamburg/Germany
5Private Urologic Practice, Bremerhaven/Germany
6Bayer Schering Pharma AG, Berlin/Germany
7Gulf Medical University, Research Dept., Ajman/UAE
Poster Board 60
AMORPHOUS NANOSILICA INDUCES MHC CLASS I-RESTRICTED PRESENTATION OF EXOGENOUS ANTIGENS
T. Yoshikawa1,2, H. Nabeshi1,2, N. Itoh1,2, Y. Yoshioka2,3, Y. Tsutsumi1,2,3,4 1Department of Toxicology and Safety Science, Graduate school of Pharmaceutical Sciences, Osaka University
2Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation (NiBio)
3The Center for Advanced Medical Engineering and Informatics, Osaka University
4Ministry of Education, Culture, Sports, Science and Technology (MEXT)
Osaka, Japan
Poster Board 61
THE INSULIN RESISTANCE ASSOCIATES WITH THE CLINICOPATHOLOGICAL CHARACTERISTICS OF PROSTATE CANCER
S.J. Yun1, W.T. Kim1, S.W. Jo2, Y.J. Kim1, S.C. Lee1, W.J. Kim1
1Department of Urology, Chungbuk National University College of Medicine, Cheongju, Korea
2Department of Urology, Cheongju Saint Mary's Hospital, Cheongju, Korea |
|
Poster Board 62
THE IMPACT OF BODY MASS INDEX ON SPERM RECOVERY AND SERUM REPRODUCTIVE HORMONE LEVELS IN NON-OBSTRUCTIVE AZOOSPERMIA
H. Hibi1, T. Ohori1, Y. Yamada2, N. Honda2, Y. Asada3
1Department of Urology, Kyoritsu General Hospital
2Department of Urology, Aichi Medical University School of Medicine
3Asada Lady’s Clinic
Poster Board 63
PENILE HYPOSPADIAS WITH CHORDEE REPAIR: A NOVEL ONE-STAGE TECHNIQUE
D.K. Radopoulos, G.P. Dimitriadis, S.S. Ioannidis, P.T. Dimopoulos, K.A. Tzakas
1st Department of Urology, Aristotle University of Thessaloniki, Greece |
Poster Board 65
PHYSIOLOGICAL PATTERN OF SECRETION OF URINARY NEUROTROPHINS IN HEALTHY MALE AND FEMALE VOLUNTEERS
A. Lopes Tiago1,2,4, R. Pinto1,2,4, S.C. Barros3,4, P. Diniz1,2,4, C. Silva1,2,4, C.D. Cruz3,4, F. Cruz1,2,4
1Department of Urology, Hospital de Sao Joao, Porto; 2Faculty of Medicine, 3Institute of Histology and Embryology, Faculty of Medicine & 4Instituto de Biologia e Molecular e Celular – IBMC, University of Porto, Porto, Portugal
Late Addition
Poster Board 69
|
|
|
|
|
WebStudio.co.il